Our study suggests that evaluation of ETV6 (possibly in combination with PIM2 to determine the ETV6/PIM2 ratio) may serve two purposes, as high ETV6 levels may correlate with poor prognosis, while low ETV6 levels may identify DLBCL patients, who could benefit from a different therapeutic intervention (e.g., inclusion of BIRC5 inhibitors, such as YM155). Here, PIM2 is linked to diffuse large B-cell lymphoma.